COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients
Orbit · 2025
DOI: 10.1080/01676830.2024.2377249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orbit, 2025. Verfasst von Usha Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orbit, Oculoplasty, Ocular Oncology and Ocular Prosthesis, Aravind Eye Hospital, Madurai, India. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19, Orbital Diseases, Eye Infections, Fungal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Columbia University.
Abstract (Originalsprache)
PURPOSE: Outbreaks of mucormycosis were reported worldwide throughout the COVID-19 pandemic. We report clinical outcomes of a treatment protocol for COVID-19-associated rhino-orbital-cerebral mucormycosis (ROCM). METHODS: Patients with biopsy-proven mucormycosis and COVID-19 were included. All received intravenous amphotericin B deoxycholate 1 mg/kg and surgical endoscopic sinus debridement (FESS). Those with rhino-orbital or cerebral disease limited to the cavernous sinus were eligible for transcutaneous retrobulbar amphotericin B (TRAMB). Patients were followed with weekly imaging, endoscopic examinations, and serial debridement as necessary. Patients were discharged on oral posaconazole for 6 months. RESULTS: In total, 264 patients were followed for a mean of 2.5 months. On presentation, 163 patients (174 eyes) had eye involvement. Of these, 141 eyes (81.0%) had light perception or worse vision. By the last follow-up, 163 patients (176 eyes) were affected, and of these, 96 eyes (54.5%) had no light perception. Twenty-one patients (8%) died and 3 orbits (0.5%) were exenterated. There was no change in mortality (p = 0.38) or exenteration (p = 0.38) in the 55 patients who received TRAMB compared to patients with rhino-orbital or cerebral disease limited to the cavernous sinus who did not. Asymptomatic COVID-19 was associated with higher mortality than symptomatic COVID-19 (p = 0.025). Uncontrolled diabetes was a risk factor for death (p = 0.022). New diabetes was associated with increased mortality versus pre-existing diabetes (p = 0.005). CONCLUSION: A multidisciplinary approach is crucial to manage COVID-19-ROCM. In our cohort, TRAMB therapy did not increase mortality or exenteration rates. While poor vision on presentation was profound, some vision recovery was noted with treatment. COVID-19 immune dysregulation may predispose patients to ROCM, particularly those with asymptomatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orbit, Oculoplasty, Ocular Oncology and Ocular Prosthesis, Aravind Eye Hospital, Madurai, India.
- Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Otolaryngology, Head and Neck Surgery, Aravind Eye Hospital, Madurai, India.
- Department of Biostatistics, Aravind Eye Hospital, Madurai, India.
- Department of Ophthalmology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Ophthalmology and International Health, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Pooja Kulkarni
Förderung
- Columbia University
Zitieren
APA
Kim, U., Perzia, B., Kulkarni, P., Rajiniganth, M., Sundar, B., Robin, A. L., Garg Shukla, A., & Maeng, M. M. (2025). COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients. Orbit. https://doi.org/10.1080/01676830.2024.2377249
Vancouver
Kim U, Perzia B, Kulkarni P, Rajiniganth M, Sundar B, Robin AL, et al. COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients. Orbit. 2025. doi:10.1080/01676830.2024.2377249
BibTeX
@article{Kim2025,
author = {Kim, Usha and Perzia, Brittany and Kulkarni, Pooja and Rajiniganth, Mahalingam and Sundar, Balagiri and Robin, Alan L and Garg Shukla, Aakriti and Maeng, Michelle M},
title = {COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients},
journal = {Orbit},
year = {2025},
doi = {10.1080/01676830.2024.2377249}
}
EUVIMED